This study aims to assess the level of participation of thoracic cancer patients undergoing definitive radiotherapy and chemotherapy ± immunotherapy in their medical processes and the association between the level of participation and patients' side effects, quality of life, and long-term survival. Additionally, this study will rate the level of participation from both the patients' and medical staff's perspectives and will compare the differences in ratings from these two viewpoints, as well as their impact on treatment outcomes.
Study Type
OBSERVATIONAL
Enrollment
500
Sun Yat-sen University
Guangzhou, China
Incidence of >=Grade 3 toxicities
The percentage of patients who develop \>=Grade 3 toxicities
Time frame: 2 years
Overall survival
2-year survival rate
Time frame: 2 years
Progression-free survival
2-year progression-free survival rate
Time frame: 2 years
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.